Partner With Us NRI

Company details

6M Return -28.72%
1Y Return -45.82%
Mkt Cap.(Cr) 30,644.61
Volume 47,699
Div Yield 0.88%
OI Chg %
Volume 47,699

Open Free Demat Account Online with ICICIDIRECT


  • swot

  • technicals

  • deals

  • shareholding


Delivery and volume

Our Research View

Trading recommendation

Data not found

Investment recommendation

Call Date

31 May 2022

Entry Price


Target Price



12-18 Month


  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio


Operating Profit(Cr.)

Profit after Tax(Cr.)


Reserves and Surplus



Operating Profit

Profit after tax





Equity Capital: 21,929.87 Cr FV: 1.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 20,712.90 -49,208.14
LAST 3M 72,514.10 -86,871.53
LAST 6M 139,386.11 -217,992.74
LAST 12M 232,044.22 -250,830.89


  • About Company
  • Company Info
  • Listing Info
  • Aurobindo Pharma is a distinguished name in the pharmaceutical industry. It was incorporated in 1986, and its headquarters is located in Hyderabad. As of 31 December 2021, it reported a net income of Rs 604.73 crore. The prominent faces in Aurobindo Pharma management are—Mr K Raghunathan, Mr K Nityananda Reddy, Dr M. Sivakumaran, Mr P. V Ram Prasad Reddy, and a few more. Aurobindo Pharma’s valuation on the stock exchange is Rs 30,636 crore. 

    The company is listed on both the stock exchanges of India, that is NSE and BSE. It is traded under the symbol AURO PHARMA. 

    The company is primarily into the development, manufacturing, and supply of active pharmaceutical ingredients, generic pharmaceuticals, and branded speciality pharmaceuticals. Some key offerings in its product portfolio cater to/include antibiotics, central nervous system, anti-diabetics, gastroenterological, anti-retroviral, and cardiovascular. The company currently supplies its products to more than 150 countries. Its subsidiary company list includes Aurolife Pharma LLC, APL Healthcare, Auro Peptides Ltd, Auronext Pharma Pvt. Ltd. and a few more. 

    Now, if you dive into the company’s financials, you will find the following.

    Aurobindo Pharma’s price-to-equity ratio or PE ratio (6.13) and price-to-book ratio or PB ratio (1.49) are better than the industry’s average. The same is the case with revenue and net income. Over the past five years, Aurobindo Pharma’s revenue and income have grown at an annual rate of 15.2% and 21.38%, respectively. For the same period, the industry’s average income and revenue growth rates were 6.94% and 8.25%, respectively. Aurobindo Pharma’s total liabilities declined by Rs 467.41 crore compared to the financial year 2020. Even after reducing the liabilities, the company cash flow statement shows a free cash flow of Rs 1455.11 crore in FY20-21. 

    On 20 May 2022, the Aurobindo Pharma share price on NSE closed at Rs 557.95. It was 6.71% higher than the previous day’s closing price. The last 52 weeks’ movement of Aurobindo Pharma Ltd.’s share price on the stock market saw a high of Rs 1,043.10 and a low of Rs 520.85. Investing in Aurobindo Pharma shares carries a low amount of risk since its price volatility is 1.95x that of the Nifty.  The key names in its peers’ list are Cipla Ltd., Torrent Pharmaceuticals Ltd., Sun Pharmaceuticals Industries Ltd., and Dr Reddy’s Laboratories Ltd.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Read More

Registered Address

Plot No 2 Maitrivihar, Behind Maithri Vanam Ameerpet, Hyderabad, Telangana, 500038

Tel : 91-40-23736370
Email : info:aurobindo.com/investorgrievances:aurobindo.co
Website : http://www.aurobindo.com


KFin Techologies Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 524804
Book Closure Date (Month) : Aug
BSE Group : A
ISIN : INE406A01037

ICICIdirect Aurobindo Pharma Ltd FAQ

You can buy Aurobindo Pharma Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Aurobindo Pharma Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Jul 01, 2022 04:01 PM the closing price of Aurobindo Pharma Ltd was ₹ 523.00.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Jul 01, 2022 04:01 PM, the market cap of Aurobindo Pharma Ltd stood at ₹ 30,644.61.
The latest PE ratio of Aurobindo Pharma Ltd as of Jul 01, 2022 04:01 PM is 10.95
The latest PB ratio of Aurobindo Pharma Ltd as of Jul 01, 2022 04:01 PM is 0.82
The 52-week high of Aurobindo Pharma Ltd is ₹ 1,012.90 while the 52-week low is ₹ 503.40 .
According to analyst recommendations, Aurobindo Pharma Ltd has a “Buy” rating for the long term.

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote